US · DARE · BIOTECHNOLOGY
Dare Bioscience, Inc. (DARE) intrinsic value and stock valuation
$0.41as of 2026-11-21 · Mkt cap 12.76M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Dare Bioscience, Inc. DCF and intrinsic value
InvestorsCraft values DARE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DARE’s statements →
Dare Bioscience, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.03M | $10K | $2.81M | $10M | $0.00 |
| Operating income | -$-13.55M | -$-23.45M | -$-30.94M | -$-31.39M | -$-39.07M |
| Net income | -$-13.4M | -$-4.05M | -$-30.16M | -$-30.95M | -$-38.7M |
| EPSd | -$-119.87K | -$-476.47K | -$-4.14M | -$-4.39M | -$-7.59M |
| Operating cash flow | -$-9.89M | $5.39M | -$-38.86M | -$-18.09M | -$-28.76M |
| Capital expenditure | -$-390K | -$-570K | -$-630K | -$-60K | -$-10K |
| Free cash flow | -$-10.27M | $4.82M | -$-39.49M | -$-18.15M | -$-28.78M |
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M |
| Total debt | $2.66M | $1.3M | $1.4M | $490K | $270K |
| Net debt | -$-22.06M | -$-14.4M | -$-9.07M | -$-34.18M | -$-51.4M |
| Total equity | $2.84M | -$-6.01M | -$-5.05M | $11.1M | $38.8M |
| Cash and short-term investments | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.03M | $10K | $2.81M | $10M | $0.00 |
| Cost of revenue | $2.45M | $14.3M | $21.6M | $30.1M | $100K |
| Gross profit | -$-1.42M | -$-14.3M | -$-18.83M | -$-20.14M | -$-100K |
| Research and development expenses | $5.52B | $14.2M | $21.5M | $30M | $30.6M |
| Selling, general and administrative expenses | $8.76M | $9.16M | $11.9M | $11.2M | $8.35M |
| Other expenses | -$-5.52B | -$-14.21M | -$-21.34M | -$-30.04M | $0.00 |
| Operating expenses | $12.1M | $9.16M | $12.1M | $11.2M | $39M |
| Cost and expenses | $14.6M | $23.5M | $33.8M | $41.4M | $39.1M |
| Interest income | $680K | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $820K | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $2.15M | $40K | $40K | $20K | $30K |
| Ebitda | -$-10.43M | -$-4.01M | -$-30.7M | -$-30.92M | -$-38.67M |
| Operating income | -$-13.55M | -$-23.45M | -$-30.94M | -$-31.39M | -$-39.07M |
| Total other income/expenses, net | $150K | $19.4M | $780K | $440K | $370K |
| Income before tax | -$-13.4M | -$-4.05M | -$-30.16M | -$-30.95M | -$-38.7M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-13.4M | -$-4.05M | -$-30.16M | -$-30.95M | -$-38.7M |
| Weighted average shares outstanding | $111.8M | $8.5M | $7.28M | $7.05M | $5.1M |
| Weighted average diluted shares outstanding | $111.8M | $8.5M | $7.28M | $7.05M | $5.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M |
| Net receivables | $570K | $230K | $950K | $1.7M | $1.15M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $27.1M | $18.5M | $17.5M | $43M | $55.3M |
| Property, plant and equipment, net | $4.4M | $2.54M | $1.98M | $520K | $240K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $340K | $0.00 | $0.00 |
| Total non-current assets | $5.41M | $3.65M | $3.74M | $790K | $510K |
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M |
| Accounts payable | $1.2M | $1.46M | $3.39M | $2.03M | $2.1M |
| Short-term debt | $2.1M | $550K | $470K | $400K | $270K |
| Deferred revenue | $19.7M | $16.6M | $13.7M | $18.3M | $10.5M |
| Total current liabilities | $23.7M | $21.6M | $20.5M | $31.6M | $16.1M |
| Long-term debt | $560K | $750K | $940K | $90K | $0.00 |
| Deferred revenue, non-current | $0.00 | $1M | $1M | $1M | $1M |
| Total non-current liabilities | $5.95M | $6.5M | $5.85M | $1.09M | $1M |
| Capital lease obligations | $2.66M | $1.3M | $1.4M | $490K | $270K |
| Total liabilities | $29.6M | $28.1M | $26.3M | $32.7M | $17.1M |
| Common stock | $0.00 | $0.00 | $10K | $10K | $10K |
| Retained earnings | -$-188.69M | -$-175.29M | -$-171.24M | -$-141.07M | -$-110.13M |
| Accumulated other comprehensive income (loss) | -$-420K | -$-430K | -$-360K | -$-350K | -$-150K |
| Total equity | $2.84M | -$-6.01M | -$-5.05M | $11.1M | $38.8M |
| Total investments | $0.00 | $0.00 | $340K | $0.00 | $0.00 |
| Total debt | $2.66M | $1.3M | $1.4M | $490K | $270K |
| Net debt | -$-22.06M | -$-14.4M | -$-9.07M | -$-34.18M | -$-51.4M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-13.4M | -$-4.05M | -$-30.16M | -$-30.95M | -$-38.7M |
| Depreciation and amortization | $2.15M | $40K | $40K | $20K | $30K |
| Stock-based compensation | $1.5M | $2.2M | $2.53M | $2.16M | $1.6M |
| Change in working capital | -$-210K | $5.81M | -$-10.43M | $10.7M | $8.73M |
| Accounts receivable | -$-340K | $720K | $750K | -$-560K | -$-690K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-260K | -$-1.93M | $1.36M | -$-80K | $1.08M |
| Net cash provided by operating activities | -$-9.89M | $5.39M | -$-38.86M | -$-18.09M | -$-28.76M |
| Investments in property, plant and equipment | -$-390K | -$-570K | -$-630K | -$-60K | -$-10K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-390K | -$-570K | -$-630K | -$-60K | -$-10K |
| Common stock issued | $20.9M | $450K | $9.35M | $1.22M | $75.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $19.3M | $430K | $15.6M | $1.34M | $75.9M |
| Net change in cash | $9.01M | $5.19M | -$-23.86M | -$-17M | $47M |
| Cash at end of period | $25M | $16M | $10.8M | $34.7M | $51.7M |
| Operating cash flow | -$-9.89M | $5.39M | -$-38.86M | -$-18.09M | -$-28.76M |
| Capital expenditure | -$-390K | -$-570K | -$-630K | -$-60K | -$-10K |
| Free cash flow | -$-10.27M | $4.82M | -$-39.49M | -$-18.15M | -$-28.78M |
Line items
Line items
Line items
About Dare Bioscience, Inc.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
- CEO
- Sabrina Martucci Johnson
- Employees
- 24
- Beta
- 1.02
Explore
Frequently asked questions
What is the intrinsic value of Dare Bioscience, Inc. (DARE)?
InvestorsCraft does not currently publish an intrinsic value for DARE. How the IC value is calculated.
Is DARE undervalued?
InvestorsCraft does not publish an undervaluation signal for DARE at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.